Clinical Trials
13 trialsNCT06880549 2026-05-27
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT06279143 2026-05-26
dOCT-pBCC
Vejle Hospital
Completed
NCT05537740 2026-05-20
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
Phase 1 Active not recruiting
NCT03686124 2026-05-13
ACTengine
Immatics US, Inc.
Phase 1/2 Recruiting
NCT06984328 2026-05-05
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Genmab
Phase 2 Active not recruiting
NCT00641381 2026-05-04
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Phase 1 Completed
NCT06854653 2026-04-29
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Phase 2 Recruiting
NCT06246227 2026-04-24
ctDNA for Early Detection of Recurrence in Melanoma
Herlev and Gentofte Hospital
Active not recruiting
NCT07535710 2026-04-17
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Shanghai Jiao Tong University School of Medicine
Phase 1/2 Not yet recruiting
NCT01384513 2026-04-15
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT05996185 2026-04-14
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Yale University
Phase 2 Recruiting
NCT02668770 2026-04-07
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05047094 2026-04-06
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
Alpha Tau Medical LTD.
Phase NA Recruiting